Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ZITFA |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | MBH-1309 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Lymphocyte antigen 75 (LY75) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
MEN-1309 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04064359 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1, open-label, dose finding study to assess the safety, tolerability, PK, and preliminary efficacy of OBT076, a CD205-directed ADC, in recurrent and/or metastatic CD205+ solid tumors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03403725 | Clinical Status | Phase 1 | ||
| Clinical Description |
Open-label, multicenter, phase 1 dose escalation study of MEN1309, a CD205 antibody-drug conjugate,in patients with CD205-positive metastatic solid tumors and non-Hodgkin lymphoma.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Inclusion criteria require patients ≥18 years with ECOG PS 0-1 and histologically confirmed recurrent/metastatic Adenoid Cystic Carcinoma (AdCC) of head/neck/trachea, demonstrating RECIST 1.1-defined progression within 6 months prior to screening. Participants must have measurable disease and adequate organ function (ANC ≥2.0×10<sup>9</sup>/L, platelets ≥100×10<sup>9</sup>/L, Hb ≥9.0 g/dL without transfusions, WBC ≥2000/mm <sup>3</sup>, AST/ALT ≤2.5×ULN [≤5×ULN with liver metastases], creatinine <1.5×ULN, bilirubin ≤1.5×ULN [<3.0 mg/dL for Gilbert's], normal potassium). Contraception requirements include: WOCBP must use highly effective contraception (failure rate <1%/year) from consent until 4 months post-treatment; males must use condoms/spermicide (with partner contraception) or refrain from semen donation during same period. All participants must have insurance coverage and provide informed consent.
Click to Show/Hide
|
||||
| Administration Dosage |
OBT076, administration at 3mg/kg, (IV ≥ 3h infusion) on Day 1 every 21 days (3-week cycle) until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment or patient refusal whichever comes first.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05930951 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase Ib Study of OBT076 or OBT076 Followed by Balstilimab in Patients with Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (AdCC) of the Head and Neck (H&N)
|
||||
| Primary Endpoint |
The primary endpoint is Objective Response Rate (ORR) assessed by investigators using RECIST 1.1 criteria, evaluated through study completion (average 1 year).
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Eligibility requires ≥18yo with metastatic CD205+ solid tumors (ECOG 0-1, measurable disease per RECIST v1.1). Breast cancer specifics: HR+ (≥2 prior endocrine therapies), HER2- (ASCO-CAP criteria), or TNBC (≥1 prior metastatic chemo). All subjects require adequate organ function, ≤5 prior chemo lines (if 3-5 lines, last dose ≥12 weeks pre-C1D1), and contraception compliance (negative pregnancy test, barrier methods, no breastfeeding/sperm donation for 4 months post-treatment).
Click to Show/Hide
|
||||
| Administration Dosage |
Intravenous (IV) infusion of OBT076 every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04064359 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include 1-year incidence of AEs (NCI CTCAE v5 grades 1-5) and dose-limiting toxicities (DLTs, grades 3-4 per NCI CTCAE v5 with duration exceptions).
|
||||
| Other Endpoint |
Secondary endpoints assess 2-year efficacy (CBR, ORR, DoR, PFS, OS via RECIST v1.1/Kaplan-Meier) and 1-year PK parameters (AUC, Cmax, Tmax, T1/2, CL, Vd) of OBT076 with full statistical reporting (N, mean, SD, CV%, median, min/max).
|
||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: AspC1) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 11.20% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: AspC1) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 14.50% | Negative CD205 expression (CD205-; IHC 0) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,3.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: AspC1) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 16.50% | Negative CD205 expression (CD205-; IHC 0) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: AspC1) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20.50% | Negative CD205 expression (CD205-; IHC 0) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: HPAFII) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 37.80% | Negative CD205 expression (CD205-; IHC 0) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer PDX model (PDX: PDX-22) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 38.70% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Bladder cancer PDX model (PDX: PDX-CTG-1652) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 49.30% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Bladder cancer PDX model (PDX: PDX-CTG-1388) | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 50% | Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: PDX-21) | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60.20% | Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: HPAFII) | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.60% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PDX-P6P) | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.60% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: HPAFII) | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.40% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer PDX model (PDX: PDX-347) | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.90% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,10 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer PDX model (PDX: HPAFII) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 22.70% | Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC70 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC70 cells | CVCL_1270 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 45.60% | Moderate CD205 expression (CD205++) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Urinary bladder cancer SW780 model | ||||
| In Vitro Model | Bladder carcinoma | SW780 cells | CVCL_1728 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 63.70% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,1.25 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC1806 CDX model | ||||
| In Vitro Model | Breast squamous cell carcinoma | HCC1806 cells | CVCL_1258 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 72.30% | High CD205 expression (CD205+++) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Urinary bladder cancer SW780 model | ||||
| In Vitro Model | Bladder carcinoma | SW780 cells | CVCL_1728 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 74% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously with a single dose, 5 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer CDX model | ||||
| In Vitro Model | Pancreatic cancer | Pancreatic cancer cells | Homo sapiens | ||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 79.90% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC1806 CDX model | ||||
| In Vitro Model | Breast squamous cell carcinoma | HCC1806 cells | CVCL_1258 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,3.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC1806 CDX model | ||||
| In Vitro Model | Breast squamous cell carcinoma | HCC1806 cells | CVCL_1258 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.50% | Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Urinary bladder cancer SW780 model | ||||
| In Vitro Model | Bladder carcinoma | SW780 cells | CVCL_1728 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.80% | Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,3.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC70 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC70 cells | CVCL_1270 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.20% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,2.5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC70 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC70 cells | CVCL_1270 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.50% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously once weekly for 2 consecutive weeks, 5 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Diffuse Large B-Cell Lymphoma CDX model | ||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.60% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC1806 CDX model | ||||
| In Vitro Model | Breast squamous cell carcinoma | HCC1806 cells | CVCL_1258 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.70% | Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,5 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Triple-negative breast cancer HCC70 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC70 cells | CVCL_1270 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.80% | Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
To test the in vivo efficacy of MEN1309/OBT076,different xenograft and PDX models were selected on the basis of the IHC analysis for CD205 staining in various tumor types. Efficacy of MEN1309/OBT076,administered with a q21dx3,10 mg/kg schedule,was determined by assessing the inhibition of tumor growth at the nadir of tumor volume in treated versus control mice and assessing mRECIST criteria adapted to the mouse from human RECIST. Mice were euthanized when tumors reached 2, 000 mm 3 or when the study endpoint was reached.
Click to Show/Hide
|
||||
| In Vivo Model | Urinary bladder cancer SW780 model | ||||
| In Vitro Model | Bladder carcinoma | SW780 cells | CVCL_1728 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
100 pM
|
High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
|
||||
| In Vitro Model | Mantle cell lymphoma | Mantle cell lymphoma cells | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
110 pM
|
High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
|
||||
| In Vitro Model | Marginal zone lymphoma | Marginal zone lymphoma cells | Homo sapiens | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
200 pM
|
High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | Diffuse large B-cell lymphoma cells | Homo sapiens | ||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
300 pM
|
Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
310 pM
|
Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
The inhibitory activity of MEN-1309 against cancer cell growth against 42 B-cell lymphoma cell lines in vitro. The cells were treated with MEN-1309 for 50 days.
|
||||
| In Vitro Model | B-cell chronic lymphocytic leukemia | PCL12 cells | CVCL_2H32 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.1 nM
|
High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.26 nM
|
Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Bladder carcinoma | SW780 cells | CVCL_1728 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.37 nM
|
|||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.4 nM
|
Negative CD205 expression (CD205-; IHC 0) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 10 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.43 nM
|
Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.71 nM
|
Moderate CD205 expression (CD205++; IHC 2+) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC70 cells | CVCL_1270 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.81 nM
|
Negative CD205 expression (CD205-; IHC 0) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Breast squamous cell carcinoma | HCC1806 cells | CVCL_1258 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.82 nM
|
|||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.32 nM
|
Low CD205 expression (CD205+; IHC 1+) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Pancreatic adenocarcinoma | SU.86.86 cells | CVCL_3881 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
14.2 nM
|
|||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
22.66 nM
|
Negative CD205 expression (CD205-; IHC 0) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | AsPC-1 cells | CVCL_0152 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
36.23 nM
|
High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
The expression of the CD205 antigen was evaluated in a panel of human pancreas,bladder,colon cancer,and TNBC cell lines. Tumor cells were incubated with MEN1309/OBT076 for 72 hours at 37°C.
|
||||
| In Vitro Model | Recurrent bladder carcinoma | HT-1197 cells | CVCL_1291 | ||
16A5-MCC-DM1 [Phase 1]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 59.90% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously once weekly for 2 consecutive weeks, 10 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Diffuse Large B-Cell Lymphoma CDX model | ||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 77.10% | High CD205 expression (CD205+++; IHC 3+) | ||
| Method Description |
The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously with a single dose, 10 mg/kg.
Click to Show/Hide
|
||||
| In Vivo Model | Pancreas cancer CDX model | ||||
| In Vitro Model | Pancreatic cancer | Pancreatic cancer cells | Homo sapiens | ||
References